Roche ex­ec Pearl Huang re­joins biotech as CEO of Cyg­nal — Flag­ship's bet on 'ex­oneur­al bi­ol­o­gy'

Mark Pearl Huang down as the lat­est il­lus­tri­ous phar­ma ex­ec to take charge of a biotech.

Jump­ing from Roche — where she was the SVP and glob­al head of ther­a­peu­tic modal­i­ties, over­see­ing every­thing from small mol­e­cule to nu­cle­ic acid-based ther­a­pies — Huang has been tapped as the CEO of Cyg­nal Ther­a­peu­tics.

A prod­uct of Flag­ship Pi­o­neer­ing’s in­no­va­tion foundry, Cyg­nal is tar­get­ing mech­a­nisms and path­ways as­so­ci­at­ed with the pe­riph­er­al ner­vous sys­tem, a struc­ture of nerves work­ing out­side the cen­tral ner­vous sys­tem, plough­ing a field they call “ex­oneur­al bi­ol­o­gy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER